DarioHealth Corp. announced on April 17, 2025, a new strategic partnership with a leading national benefit administrator. This collaboration will deliver Dario's comprehensive cardiometabolic solution, including a GLP-1 support program and its full AI-driven digital health suite, to employers. Initial clients have already been implemented and are contributing to revenue since January 2025.
This marks Dario's first national benefit administrator partnership, representing a strategic step towards broader adoption across benefit administration channels. The partnership targets the rapidly growing GLP-1 market, projected to reach $100 billion by 2030, and the broader cardiometabolic disease market, expected to surpass $1.2 trillion by 2033. Dario's solution addresses the high discontinuation rates of GLP-1 medications by providing comprehensive behavioral support.
Steven Nelson, Chief Commercial Officer, stated that this partnership unlocks new distribution channels and expands the employer market, with a shorter sales cycle enabling quick onboarding of employers. This foundational entry into a priority growth segment is expected to have an immediate impact on Dario's Business-to-Business-to-Consumer (B2B2C) recurring revenues for 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.